Genprex, Inc. - GNPX STOCK NEWS

Genprex (NASDAQ: GNPX) has announced plans to create a new subsidiary focused on developing GPX-002, a gene therapy for Type 1 and Type 2 diabetes. This move aims to separate the diabetes program from Genprex's oncology portfolio, potentially attracting more investors and expediting clinical development. The spin-out is expected to occur by the end of 2024, subject to financing and board approval.

The new company would become a pure-play diabetes-focused biopharmaceutical entity, while Genprex would concentrate on oncology. GPX-002, licensed from the University of Pittsburgh, uses an AAV vector containing Pdx1 and MafA genes administered directly into the pancreatic duct. This approach could potentially replace daily blood glucose monitoring and insulin therapy, as well as GLP-1 treatments in Type 2 diabetes.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has announced its participation in two major investor and industry conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-13, with an on-demand virtual presentation by Ryan Confer, Genprex's President, CEO, and CFO, available from September 9-11.

Additionally, Genprex will attend Chardan's 8th Annual Genetic Medicines Conference from September 30 to October 1 in New York City. Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will be available for in-person meetings at this event. These presentations will highlight Genprex's innovative gene therapies for cancer and diabetes, offering investors insights into the company's progress and potential.

Genprex (NASDAQ: GNPX) has released a new video featuring Chief Medical Officer Dr. Mark Berger discussing positive patient outcomes in two lung cancer clinical trials. The Acclaim-1 trial, evaluating Reqorsa® Gene Therapy with Tagrisso® for late-stage NSCLC, showed remarkable prolonged Progression Free Survival in two patients. In the Acclaim-3 trial, testing Reqorsa with Tecentriq® for extensive stage small cell lung cancer, the first patient achieved a partial remission during maintenance therapy.

Dr. Berger highlighted the significance of these results and announced updates to the oncology clinical development program. Genprex is streamlining its efforts by removing a cohort in Acclaim-1's Phase 2a and closing Acclaim-2 to further enrollment due to slow recruitment. The company aims to focus resources on advancing Reqorsa through the clinic efficiently.

Genprex (NASDAQ: GNPX) announced positive updates for its Acclaim-1 and Acclaim-3 clinical trials treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with Reqorsa® Gene Therapy. In Acclaim-1, two patients showed prolonged Progression Free Survival, with one maintaining a Partial Remission for over two years. The first patient in Acclaim-3 achieved a Partial Remission during maintenance therapy.

Genprex is refocusing its oncology program, discontinuing Acclaim-2 and limiting Acclaim-1's Phase 2a to patients with prior Tagrisso treatment only. The company expects to complete enrollment for Acclaim-1's Phase 2a first 19 patients and conduct an interim analysis in H1 2025. Acclaim-3's Phase 2 expansion is anticipated to start in H2 2024.

Genprex is also collaborating with an academic partner to develop biomarkers for patient selection and treatment response prediction.

Genprex (NASDAQ: GNPX) has been granted a patent in Singapore for its lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies for cancer treatment. This patent, valid through 2037, expands on previously granted patents in other countries and covers the use of REQORSA with immune checkpoint inhibitors. The company plans to pursue additional patents for REQORSA combined with PD-L1 antibodies in various countries, which could apply to their Acclaim-3 clinical trial.

The patent strengthens Genprex's intellectual property portfolio, particularly in Asian markets where lung cancer is prevalent. In 2022, Asia accounted for 63% of new lung cancer cases worldwide. The Acclaim-3 study, a Phase 1/2 clinical trial, combines REQORSA with Genentech's Tecentriq® for extensive stage small cell lung cancer (ES-SCLC) patients. This trial has received FDA Fast Track Designation and Orphan Drug Designation.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Sidoti Microcap Conference on August 15, 2024, at 8:30 am ET. Ryan Confer, the company's President, CEO, and CFO, will provide an overview of Genprex's gene therapies for cancer and diabetes.

The virtual presentation will highlight the company's pioneering work in developing life-changing therapies. Investors can access the presentation through a provided link and schedule virtual meetings with Mr. Confer. An archive of the presentation will be available on the company's website in the Investor Relations section.

This conference appearance underscores Genprex's commitment to advancing its innovative gene therapy pipeline and engaging with the investment community.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced significant achievements in its 2024 stockholder letter. The company has initiated two new lung cancer clinical trials and continues treating patients in an ongoing trial. By partnering with community-based oncology practices, Genprex aims to extend its clinical reach. They have also expanded preclinical research into new therapeutic areas, showcasing positive results at a major cancer conference. Additionally, their global intellectual property portfolio has been strengthened to protect their lead drug candidate. Genprex is optimistic about upcoming catalysts that will enhance its position in gene therapy.

Genprex, a clinical-stage gene therapy company, announced its participation in the 2024 BIO International Convention, set to take place from June 3-6, 2024, at the San Diego Convention Center. The company's President, CEO, and CFO, Ryan Confer, will present on June 3 at 2:00 p.m. PT. The presentation will cover Genprex's gene therapies for cancer and diabetes. Attendees can request one-on-one meetings through the conference portal or by contacting Investor Relations.

Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, is supported by FDA Orphan Drug and Fast Track designations. Genprex highlighted the poor prognosis of ES-SCLC and the benefits of current treatments, emphasizing the potential of their therapy. Positive outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer have enabled an accelerated timeline for Acclaim-3.